Telix, A Biopharmaceutical Company, Announces That Health Canada Has Approved Illuccix [Kit For The Preparation Of Gallium (68Ga) Gozetotide Injection] For Use In Staging And Re-Staging Intermediate And High-Risk Prostate Cancer And Localizing Tumour Tissue In Recurrent Prostate Cancer.Illuccix [Kit For The Preparation Of Gallium (68Ga) Gozetotide Injection], After Radiolabeling With Gallium (68Ga), Is Indicated For Use With The Positron Emission Tomography (Pet) Of Prostate Specific Membrane Antigen (Psma) Positive Lesions In Men With Prostate Cancer: With Suspected Metastasis Who Are Suitable For Initial Definitive Therapy; With Suspected Recurrence With Elevated Serum Prostate Specific Antigen (Psa) Level.
